Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients

Area of Science:

• Immunology
• Cardiovascular Science
• Transplantation Medicine

Background:

• Atherosclerotic cardiovascular disease is a leading cause of mortality in renal transplant recipients.
• Monocytes, particularly CD16+ subpopulations, are key players in atherosclerotic lesion development.
• Understanding monocyte heterogeneity is crucial for assessing cardiovascular risk in transplant patients.

Purpose of the Study:

• To investigate the association between circulating CD16+ monocyte frequency and subclinical atherosclerosis in renal transplant recipients.
• To compare monocyte subpopulations in transplant patients versus hemodialysis patients.
• To explore the influence of immunosuppressive therapy, specifically methylprednisolone, on monocyte populations and atherosclerosis.

Main Methods:

• Quantification of monocyte subpopulations (CD14++CD16+ and CD14+CD16+) in 95 renal transplant (TX) and 31 hemodialysis (HD) patients.
• Assessment of subclinical atherosclerosis in TX patients using carotid intima-media thickness (IMT).
• Statistical analysis including correlation and multivariate regression to determine associations.

Main Results:

• TX patients exhibited lower frequencies of CD16+ monocytes compared to HD patients.
• Patients on methylprednisolone (MP) therapy showed reduced CD14+CD16+ monocyte counts.
• CD14+CD16+ monocyte frequency positively correlated with IMT in TX recipients, an association independent of traditional cardiovascular risk factors.

Conclusions:

• The frequency of proinflammatory CD14+CD16+ monocytes is independently associated with subclinical atherosclerosis in renal transplant recipients.
• CD16+ monocyte heterogeneity should be considered in future studies on atherosclerosis in transplant populations.
• These findings suggest a potential role for CD14+CD16+ monocytes as a biomarker for cardiovascular risk in this patient group.